Literature DB >> 20071356

Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

Joep H M van Esch1, Florian Gembardt, Anja Sterner-Kock, Silvia Heringer-Walther, Thu H Le, Dirk Lassner, Theo Stijnen, Thomas M Coffman, Heinz-Peter Schultheiss, A H Jan Danser, Thomas Walther.   

Abstract

AIMS: Our aim was to determine the contribution of the three angiotensin (Ang) II receptor subtypes (AT(1a), AT(1b), AT(2)) to coronary responsiveness, cardiac histopathology, and tissue Ang II levels using mice deficient for one, two, or all three Ang II receptors. METHODS AND
RESULTS: Hearts of knockout mice and their wild-type controls were collected for histochemistry or perfused according to Langendorff, and kidneys were removed to measure tissue Ang II. Ang II dose-dependently decreased coronary flow (CF) and left ventricular systolic pressure (LVSP), and these effects were absent in all genotypes deficient for AT(1a), independently of AT(1b) and AT(2). The deletion of Ang II receptors had an effect neither on the morphology of medium-sized vessels in the heart nor on the development of fibrosis. However, the lack of both AT(1) subtypes was associated with atrophic changes in the myocardium, a reduced CF and a reduced LVSP. AT(1a) deletion alone, independently of the presence or absence of AT(1b) and/or AT(2), reduced renal Ang II by 50% despite a five-fold rise of plasma Ang II. AT(1b) deletion, on top of AT(1a) deletion (but not alone), further decreased tissue Ang II, while increasing plasma Ang II. In mice deficient for all three Ang II receptors, renal Ang II was located only extracellularly.
CONCLUSION: The lack of both AT(1) subtypes led to a baseline reduction of CF and LVSP, and the effects of Ang II on CF and LVSP were found to be exclusively mediated via AT(1a). The lack of AT(1a) or AT(1b) does not influence the development or maintenance of normal cardiac morphology, whereas deficiency for both receptors led to atrophic changes in the heart. Renal Ang II levels largely depend on AT(1) binding of extracellularly generated Ang II, and in the absence of all three Ang II receptors, renal Ang II is only located extracellularly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071356      PMCID: PMC2868177          DOI: 10.1093/cvr/cvq004

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  45 in total

Review 1.  Local renin-angiotensin systems: the unanswered questions.

Authors:  A H Jan Danser
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

Review 2.  Cardiac angiotensin II: an intracrine hormone?

Authors:  Martin P Schuijt; A H Jan Danser
Journal:  Am J Hypertens       Date:  2002-12       Impact factor: 2.689

3.  Subcellular localization of angiotensin II in kidney and adrenal.

Authors:  J P van Kats; J R van Meegen; P D Verdouw; D J Duncker; M A Schalekamp; A H Danser
Journal:  J Hypertens       Date:  2001-03       Impact factor: 4.844

4.  Negative inotropic effects of angiotensin II, endothelin-1 and phenylephrine in indo-1 loaded adult mouse ventricular myocytes.

Authors:  Kiyoharu Sakurai; Ikuo Norota; Hisao Tanaka; Isao Kubota; Hitonobu Tomoike; Masao Endo
Journal:  Life Sci       Date:  2002-01-25       Impact factor: 5.037

5.  Intracellular angiotensin II induces cell proliferation independent of AT1 receptor.

Authors:  Kenneth M Baker; Rajesh Kumar
Journal:  Am J Physiol Cell Physiol       Date:  2006-06-14       Impact factor: 4.249

6.  Intrarenal angiotensin II: interstitial and cellular levels and site of production.

Authors:  J P van Kats; M A Schalekamp; P D Verdouw; D J Duncker; A H Danser
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

7.  Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor.

Authors:  Jia L Zhuo; John D Imig; Timothy G Hammond; Sheyla Orengo; Edmund Benes; L Gabriel Navar
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

8.  Measurement of the activation time of oxidative phosphorylation in isolated mouse hearts.

Authors:  L A Gustafson; J H Van Beek
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-12       Impact factor: 4.733

9.  Cyclic fluctuations in the cardiac performance of the isolated Langendorff-perfused mouse heart: pyruvate abolishes the fluctuations and has an anti-ischaemic effect.

Authors:  Q-D Wang; S Tokuno; G Valen; P-O Sjöquist; P Thorén
Journal:  Acta Physiol Scand       Date:  2002-08

10.  Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.

Authors:  Satyanarayana S V Padi; Kanwaljit Chopra
Journal:  Pharmacol Res       Date:  2002-05       Impact factor: 7.658

View more
  17 in total

1.  Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Authors:  Lodi C W Roksnoer; Richard van Veghel; René de Vries; Ingrid M Garrelds; Usha M Bhaggoe; Edith C H Friesema; Frank P J Leijten; Marko Poglitsch; Oliver Domenig; Marian C Clahsen-van Groningen; Ewout J Hoorn; A H Jan Danser; Wendy W Batenburg
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

Review 2.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Intrarenal transfer of an intracellular fluorescent fusion of angiotensin II selectively in proximal tubules increases blood pressure in rats and mice.

Authors:  Xiao C Li; Julia L Cook; Isabelle Rubera; Michel Tauc; Fan Zhang; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-09

Review 4.  Functional relevance of biased signaling at the angiotensin II type 1 receptor.

Authors:  Douglas G Tilley
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2011-06       Impact factor: 2.895

5.  No Brain Renin-Angiotensin System: Déjà vu All Over Again?

Authors:  Curt D Sigmund; Debra I Diz; Mark C Chappell
Journal:  Hypertension       Date:  2017-04-10       Impact factor: 10.190

Review 6.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

7.  Impact of AT2 receptor deficiency on postnatal cardiovascular development.

Authors:  Daniel Biermann; Andreas Heilmann; Michael Didié; Saskia Schlossarek; Azadeh Wahab; Michael Grimm; Maria Römer; Hermann Reichenspurner; Karim R Sultan; Anna Steenpass; Süleyman Ergün; Sonia Donzelli; Lucie Carrier; Heimo Ehmke; Wolfram H Zimmermann; Lutz Hein; Rainer H Böger; Ralf A Benndorf
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

8.  Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade.

Authors:  Els Moltzer; Luuk te Riet; Sigrid M A Swagemakers; Paula M van Heijningen; Marcel Vermeij; Richard van Veghel; Angelique M Bouhuizen; Joep H M van Esch; Stephanie Lankhorst; Natasja W M Ramnath; Monique C de Waard; Dirk J Duncker; Peter J van der Spek; Ellen V Rouwet; A H Jan Danser; Jeroen Essers
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

Review 9.  Advances in use of mouse models to study the renin-angiotensin system.

Authors:  Jacqueline M Emathinger; Jonathan W Nelson; Susan B Gurley
Journal:  Mol Cell Endocrinol       Date:  2021-03-28       Impact factor: 4.369

10.  A provisional gene regulatory atlas for mouse heart development.

Authors:  Hailin Chen; Vincent VanBuren
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.